Ibotta (NYSE:IBTA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Ibotta: A Non-Rewarding Experience [Seeking Alpha]
Ibotta returns to downtown Denver with headquarters on 16th Street [CBS News]
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law Office is Investigating Claims on Your Behalf
5 Must-Read Analyst Questions From Ibotta's Q3 Earnings Call [Yahoo! Finance]